Reata Pharmaceuticals Inc (NASDAQ:RETA) major shareholder James W. Traweek, Jr. purchased 121,725 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were purchased at an average price of $24.88 per share, for a total transaction of $3,028,518.00. Following the completion of the acquisition, the insider now owns 35 shares of the company’s stock, valued at approximately $870.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Reata Pharmaceuticals Inc (NASDAQ:RETA) traded up $0.27 during trading on Friday, reaching $25.10. 484,510 shares of the company traded hands, compared to its average volume of 128,171. Reata Pharmaceuticals Inc has a 1-year low of $19.48 and a 1-year high of $40.88. The company has a debt-to-equity ratio of -0.15, a quick ratio of 3.18 and a current ratio of 3.18.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its quarterly earnings data on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million for the quarter, compared to analyst estimates of $12.54 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. research analysts anticipate that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current year.

Several research firms recently weighed in on RETA. Robert W. Baird restated a “buy” rating and set a $47.00 price target on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. Zacks Investment Research upgraded shares of Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 24th. ValuEngine cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group restated a “buy” rating and set a $44.00 price target on shares of Reata Pharmaceuticals in a report on Friday, October 6th. Finally, Leerink Swann began coverage on shares of Reata Pharmaceuticals in a report on Wednesday, September 13th. They set an “outperform” rating and a $43.00 price target on the stock. Three investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $54.71.

A number of hedge funds have recently made changes to their positions in RETA. Sphera Funds Management LTD. bought a new stake in Reata Pharmaceuticals in the third quarter worth about $6,376,000. Emerald Mutual Fund Advisers Trust raised its position in Reata Pharmaceuticals by 60.9% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock worth $14,712,000 after acquiring an additional 179,124 shares during the period. FMR LLC raised its position in Reata Pharmaceuticals by 74.4% in the second quarter. FMR LLC now owns 414,491 shares of the company’s stock worth $13,114,000 after acquiring an additional 176,885 shares during the period. Emerald Advisers Inc. PA raised its position in Reata Pharmaceuticals by 40.1% in the third quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock worth $17,709,000 after acquiring an additional 162,990 shares during the period. Finally, Vanguard Group Inc. raised its position in Reata Pharmaceuticals by 109.6% in the second quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock worth $9,350,000 after acquiring an additional 154,515 shares during the period. 29.61% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/15/reata-pharmaceuticals-inc-reta-major-shareholder-buys-3028518-00-in-stock.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.